In any work or process documents that are needed before initiation, Between or generally the end of the process just like in a clinical trial those “Documents which permit evaluation of the conduct of a trial and the quality of the data produced. It is given in the 8th section of the ICH-GCP.
Essential Documents For the Conduct of Clinical TrialClinosolIndia
The conduct of a clinical trial involves the generation and maintenance of various essential documents to ensure compliance with regulatory requirements and Good Clinical Practice (GCP) guidelines. These documents serve as a record of the trial and provide evidence of the study's conduct, integrity, and participant protection. Here are some essential documents commonly required for the conduct of a clinical trial
Investigators play a crucial role in conducting clinical research studies and ensuring the integrity, safety, and ethical conduct of the trials. Here are some key responsibilities of investigators in clinical research
In any work or process documents that are needed before initiation, Between or generally the end of the process just like in a clinical trial those “Documents which permit evaluation of the conduct of a trial and the quality of the data produced. It is given in the 8th section of the ICH-GCP.
Essential Documents For the Conduct of Clinical TrialClinosolIndia
The conduct of a clinical trial involves the generation and maintenance of various essential documents to ensure compliance with regulatory requirements and Good Clinical Practice (GCP) guidelines. These documents serve as a record of the trial and provide evidence of the study's conduct, integrity, and participant protection. Here are some essential documents commonly required for the conduct of a clinical trial
Investigators play a crucial role in conducting clinical research studies and ensuring the integrity, safety, and ethical conduct of the trials. Here are some key responsibilities of investigators in clinical research
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...Dr B Naga Raju
Presentation on Roles and Responsibilities of sponsor in conducting clinical trials as per GCP-ICH for pursuing a subject in the course of PharmD programme under RGUHS
Investigators Responsibilities during Clinical trialsBHAVYARAJAN2
This Presentation was presented by Pruthvi raj, Tejaswini, and myself Bhavya Rajan at Clinosol Research Pvt Ltd. We would like to thank Clinosol and Mujeeb sir for this opportunity. for constantly supporting and encouraging us
Presentation working on clinical trialsSarah Henter
Working on Clinical Trials – Getting started
Very few clinical trials are conducted only in one country; many are available in a variety of different sites in different places, so the translation and linguistic adaptation for different target cultures and languages becomes more important – but it’s not easy to find professionals who specialize in this specific field. With my presentation I hope to provide an overview of what makes the linguistic work on clinical trials so special, what kind of texts and target audiences there are and what knowledge linguists need to acquire in order to efficiently work in this area. This is especially interesting for translators who already specialize in the medical field, but also for linguists interested in legal, business, marketing and related field who would like to add an interesting niche with high demand to their specialization.
The presentation aims to be an introduction to the characteristics and requirements of the linguistic work on texts related to clinical trials. It not only wants to give a brief overview of how clinical trials work and who the stakeholders are, but also underline the skills and knowledge set linguists who would like to further specialize in this field should acquire. It also provides them with the necessary resources to get them started. The main topics are as follows:
• Introduction to clinical trials (what are they; how do they work; who is implied)
• Types of documents used in clinical trials (medical [specialist facing/ patient facing]; legal; marketing, etc.)
• Types of audiences (doctors/investigators/healthcare providers; patients/ other laymen such as healthy subjects/ partners/ legal representatives/ parents, etc.; ECs; CROs…)
• What skills do linguists need to work in this field?
• How to acquire that knowledge?
- Where to find glossaries/ templates/ further information
- MOOCs to take to get you started
- Books you should have read
- Other handy resources
Guidelines for Preparation of Documents, Clinical Study Report Clinical Trial...Dinesh Gangoda
Contents
Guidelines for Preparation of Documentation
Clinical Study Reports
Clinical Trial Monitoring
Safety Monitoring in clinical trials
Introduction
Proper documentation is critical to the success of a clinical study.
Every aspect of the study must be documented in order to obtain useful data and demonstrate compliance with Good Clinical Practice (GCP) guidelines and with all applicable regulations.
Investigator’s Brochure (IB)
List of Abbreviations
Contents & Summary
Introduction provides the chemical name (and generic and trade names, if approved) of the investigational product.
Physical, chemical and pharmaceutical properties and formulation of the medicinal product. Non-clinical studies & Clinical Studies and their results.
The Investigator's Brochure should be reviewed at least annually and revised as necessary in compliance with a standard procedures established by drug development company.
TSDP tells about the essential documents that are required for the #conduct of a clinical trial. For #regulatory medical writing training, contact hello@turacoz.in.
Assignment on Regulatory Prespectives of Clinical TrialsDeepak Kumar
Assignment on Origin and Principles of International Conference on Harmonization - Good Clinical Practice, (ICH-GCP) guidelines Ethical Committee- Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant-Schedule Y, ICMR
Roles and Responsibilities of sponsor, CRO, and investigator MOHAMMEDSALEEMJM
This slide mainly includes Roles and responsibilities of sponsor CRO and Investigator in Ethical conduct of Clinical Research as per ICH GCP Guidelines
Required mainly for Regulatory affairs students
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...Dr B Naga Raju
Presentation on Roles and Responsibilities of sponsor in conducting clinical trials as per GCP-ICH for pursuing a subject in the course of PharmD programme under RGUHS
Investigators Responsibilities during Clinical trialsBHAVYARAJAN2
This Presentation was presented by Pruthvi raj, Tejaswini, and myself Bhavya Rajan at Clinosol Research Pvt Ltd. We would like to thank Clinosol and Mujeeb sir for this opportunity. for constantly supporting and encouraging us
Presentation working on clinical trialsSarah Henter
Working on Clinical Trials – Getting started
Very few clinical trials are conducted only in one country; many are available in a variety of different sites in different places, so the translation and linguistic adaptation for different target cultures and languages becomes more important – but it’s not easy to find professionals who specialize in this specific field. With my presentation I hope to provide an overview of what makes the linguistic work on clinical trials so special, what kind of texts and target audiences there are and what knowledge linguists need to acquire in order to efficiently work in this area. This is especially interesting for translators who already specialize in the medical field, but also for linguists interested in legal, business, marketing and related field who would like to add an interesting niche with high demand to their specialization.
The presentation aims to be an introduction to the characteristics and requirements of the linguistic work on texts related to clinical trials. It not only wants to give a brief overview of how clinical trials work and who the stakeholders are, but also underline the skills and knowledge set linguists who would like to further specialize in this field should acquire. It also provides them with the necessary resources to get them started. The main topics are as follows:
• Introduction to clinical trials (what are they; how do they work; who is implied)
• Types of documents used in clinical trials (medical [specialist facing/ patient facing]; legal; marketing, etc.)
• Types of audiences (doctors/investigators/healthcare providers; patients/ other laymen such as healthy subjects/ partners/ legal representatives/ parents, etc.; ECs; CROs…)
• What skills do linguists need to work in this field?
• How to acquire that knowledge?
- Where to find glossaries/ templates/ further information
- MOOCs to take to get you started
- Books you should have read
- Other handy resources
Guidelines for Preparation of Documents, Clinical Study Report Clinical Trial...Dinesh Gangoda
Contents
Guidelines for Preparation of Documentation
Clinical Study Reports
Clinical Trial Monitoring
Safety Monitoring in clinical trials
Introduction
Proper documentation is critical to the success of a clinical study.
Every aspect of the study must be documented in order to obtain useful data and demonstrate compliance with Good Clinical Practice (GCP) guidelines and with all applicable regulations.
Investigator’s Brochure (IB)
List of Abbreviations
Contents & Summary
Introduction provides the chemical name (and generic and trade names, if approved) of the investigational product.
Physical, chemical and pharmaceutical properties and formulation of the medicinal product. Non-clinical studies & Clinical Studies and their results.
The Investigator's Brochure should be reviewed at least annually and revised as necessary in compliance with a standard procedures established by drug development company.
TSDP tells about the essential documents that are required for the #conduct of a clinical trial. For #regulatory medical writing training, contact hello@turacoz.in.
Assignment on Regulatory Prespectives of Clinical TrialsDeepak Kumar
Assignment on Origin and Principles of International Conference on Harmonization - Good Clinical Practice, (ICH-GCP) guidelines Ethical Committee- Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant-Schedule Y, ICMR
Roles and Responsibilities of sponsor, CRO, and investigator MOHAMMEDSALEEMJM
This slide mainly includes Roles and responsibilities of sponsor CRO and Investigator in Ethical conduct of Clinical Research as per ICH GCP Guidelines
Required mainly for Regulatory affairs students
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
2. Introduction
Before the Clinical Phase of the Trial Commences
During the Clinical Conduct of the Trial
After Completion or Termination of the Trial
Reference
2
3. Essential documents are those documents which individually and collectively permit
evaluation of the conduct of a trial and the quality of the data produced.
These documents serve to demonstrate the compliance of the investigator, sponsor and
monitor with the standards of Good Clinical Practice and with all applicable regulatory
requirements.
The various documents are grouped in three sections according to the stage of the trial
during which they will normally be generated:
I. before the clinical phase of the trial commences,
II. during the clinical conduct of the trial,
III. after completion or termination of the trial
Trial master files should be established at the beginning of the trial, both at the
investigator/institution’s site and at the sponsor's office.
Any or all of the documents addressed in this guideline may be subject to, and should be
available for, audit by the sponsor’s auditor and inspection by the regulatory
authority(ies).
3
4. S.
No.
Title of Document Purpose
Located in files of
Investigator/
Institution
Sponsor
1.
INVESTIGATOR’S
BROCHURE
To document that relevant and
current scientific information
about the investigational
product has been provided to
the investigator
X X
2. SIGNED PROTOCOL AND
AMENDMENTS, IF ANY, AND
SAMPLE CASE REPORT
FORM (CRF)
To document investigator and
sponsor agreement to the
protocol/amendment(s) and
CRF
X X
3. INFORMATION GIVEN TO
TRIAL SUBJECT
- INFORMED CONSENT
FORM (including all applicable
translations)
To document the informed
consent X X
4
5. S. No. Title of Document Purpose
Located in files of
Investigator/
Institution
Sponsor
- ANY OTHER WRITTEN
INFORMATION
To document that subjects will be
given appropriate written information
(content and wording) to support their
ability to give fully informed consent
X X
ADVERTISEMENT FOR
SUBJECT RECRUITMENT (if
used)
To document that recruitment
measures are appropriate and not
coercive
X
4. FINANCIAL ASPECTS OF
THE TRIAL
To document the financial agreement
between the investigator/institution
and the sponsor for the trial
X X
5. INSURANCE STATEMENT
(where required)
To document that compensation to
subject(s) for trial-related injury will
be available
X X
5
6. S. No. Title of Document Purpose
Located in files of
Investigator/
Institution
Sponsor
6.
SIGNED AGREEMENT
BETWEEN INVOLVED
PARTIES, e.g.:
- investigator/institution
and sponsor
- investigator/institution
and CRO
- sponsor and CRO
- investigator/institution
and authority(ies)
(where required)
To document agreements
X
X
X
X
X (w.r)
X
X
7.
REGULATORY
AUTHORITY(IES)
AUTHORISATION/APPROV
AL/ NOTIFICATION OF
PROTOCOL (where
required)
To document appropriate
authorization/approval/notification
by the regulatory authority(ies) has
been obtained prior to initiation of
the trial in compliance with the
applicable regulatory requirements
X
(Where
required)
X
(Where
required)
6
7. S. No. Title of Document Purpose
Located in files of
Investigator/
Institution
Sponsor
8.
DATED, DOCUMENTED
APPROVAL/FAVOURABLE OPINION OF
INSTITUTIONAL REVIEW BOARD (IRB)
/INDEPENDENT ETHICS COMMITTEE
(IEC) OF THE FOLLOWING:
- protocol and any amendments
- CRF (if applicable)
- informed consent form(s)
- any other written information to be
provided to the subject(s)
- advertisement for subject recruitment (if
used)
- subject compensation (if any)
- any other documents given approval/
favourable opinion
To document that
the trial has been
subject to IRB/IEC
review and given
approval/favourable
opinion. To identify
the version number
and date of the
document(s).
X X
9.
INSTITUTIONAL REVIEW
BOARD/INDEPENDENT ETHICS
COMMITTEE COMPOSITION
To document that
the IRB/IEC is
constituted in
agreement with
GCP
X X
(where
required)
7
8. S. No. Title of Document Purpose
Located in files of
Investigator/
Institution
Sponsor
10.
CURRICULUM VITAE
AND/OR OTHER RELEVANT
DOCUMENTS EVIDENCING
QUALIFICATIONS OF
INVESTIGATOR(S) AND SUB-
INVESTIGATOR(S)
To document qualifications and
eligibility to conduct trial and/or
provide medical supervision of
subjects
X X
)
11.
NORMAL
VALUE(S)/RANGE(S) FOR
MEDICAL/
LABORATORY/TECHNICAL
PROCEDURE(S) AND/OR
TEST(S) INCLUDED IN THE
PROTOCOL
To document normal values and/or
ranges of the tests
X X
12.
SAMPLE OF LABEL(S)
ATTACHED TO
INVESTIGATIONAL
PRODUCT CONTAINER(S)
To document compliance with
applicable labelling regulations and
appropriateness of instructions
provided to the subjects
X
8
9. S. No. Title of Document Purpose
Located in files of
Investigator/
Institution
Sponsor
13. MEDICAL/LABORATORY/TEC-
HNICAL PROCEDURES
/TESTS
- certification or
- accreditation or
- established quality control
and/or external quality
assessment or
- other validation
(where required)
To document competence of
facility to perform required
test(s), and support reliability of
results.
X
(where
required)
X
14. INSTRUCTIONS FOR
HANDLING OF
INVESTIGATIONAL
PRODUCT(S) AND TRIAL-
RELATED MATERIALS (if not
included in protocol or
Investigator’s Brochure)
To document instructions
needed to ensure proper storage,
packaging, dispensing and
disposition of investigational
products and trial-related
materials
X X
15. CERTIFICATE(S) OF
ANALYSIS OF
INVESTIGATIONAL
To document identity, purity,
and strength of investigational
product(s) to be used in the trial
X 9
10. S. No. Title of Document Purpose
Located in files of
Investigator/
Institution
Sponsor
16.
SHIPPING RECORDS
FOR
INVESTIGATIONAL
PRODUCT(S) AND
TRIAL-RELATED
MATERIALS
To document shipment dates, batch numbers
and method of shipment of investigational
product(s) and trial-related materials. Allows
tracking of product batch, review of shipping
conditions, and accountability
X X
17.
DECODING
PROCEDURES FOR
BLINDED TRIALS
To document how, in case of an emergency,
identity of blinded investigational product
can be revealed without breaking the blind
for the remaining subjects' treatment
X
X
(third party if
applicable)
18.
MASTER
RANDOMISATION
LIST
To document method for randomization of
trial population
X
(third party if
applicable)
19.
PRE-TRIAL
MONITORING
REPORT
To document that the site is suitable for the
trial X
20.
TRIAL INITIATION
MONITORING
REPORT
To document that trial procedures were
reviewed with the investigator and the
investigator’s trial staff
X X 10
11. S. No. Title of Document Purpose
Located in files of
Investigator/
Institution
Sponsor
1.
INVESTIGATOR’S
BROCHURE UPDATES
To document that investigator is
informed in a timely manner of relevant
information as it becomes available
X X
2.
ANY REVISION TO:
- protocol/amendment(s) and
CRF
- informed consent form
- any other written
information
provided to subjects
- advertisement for subject
recruitment (if used)
To document revisions of these trial
related documents that take effect
during trial
X X
11
12. S. No. Title of Document Purpose
Located in files of
Investigator/
Institution
Sponsor
3.
DATED, DOCUMENTED
APPROVAL/FAVOURABLE OPINION OF
INSTITUTIONAL REVIEW BOARD (IRB)
/INDEPENDENT ETHICS COMMITTEE (IEC)
OF THE FOLLOWING:
- protocol amendment(s)
- revision(s) of:
- informed consent form
- any other written information to be
provided to the subject
- advertisement for subject recruitment (if
used)
- any other documents given approval/favorable
opinion
- continuing review of trial (where required)
To document
that the
amendment(s)
and/or
revision(s) have
been subject to
IRB/IEC review
and were given
approval/favora
ble opinion. To
identify the
version number
and date of the
document(s).
X X
4.
REGULATORY AUTHORITY(IES)
AUTHORISATIONS/APPROVALS/NOTIFIC
ATIONS WHERE REQUIRED FOR:
- protocol amendment(s) and other documents
To document
compliance
with applicable
regulatory
requirements
X
(where
required)
X
12
13. S. No. Title of Document Purpose
Located in files of
Investigator/
Institution
Sponsor
5.
CURRICULUM VITAE FOR NEW
INVESTIGATOR(S) AND/OR
SUBINVESTIGATOR(S)
To document
qualifications and
eligibility to conduct
trial and/or provide
medical supervision of
subjects
X X
6.
UPDATES TO NORMAL
VALUE(S)/RANGE(S) FOR MEDICAL/
LABORATORY/ TECHNICAL
PROCEDURE(S)/TEST(S) INCLUDED IN
THE PROTOCOL
To document normal
values and ranges that
are revised during the
trial
X X
7.
UPDATES OF MEDICAL/LABORATORY/
TECHNICAL PROCEDURES/TESTS -
certification or ,accreditation or ,established
quality control and/or external quality
assessment or, other validation (where
required)
To document that tests
remain adequate
throughout the trial
period
X
(where
Required)
X
8.
MONITORING VISIT REPORTS To document site visits
by, and findings of, the X 13
14. S. No. Title of Document Purpose
Located in files of
Investigator/
Institution
Sponsor
9.
DOCUMENTATION OF
INVESTIGATIONAL
PRODUCT(S) AND TRIAL-
RELATED MATERIALS
SHIPMENT
To document shipment dates, batch
numbers and method of shipment of
investigational product(s) and trial-
related materials. Allows tracking of
product batch, review of shipping
conditions, and accountability
X X
10.
CERTIFICATE(S) OF
ANALYSIS FOR NEW
BATCHES OF
INVESTIGATIONAL
PRODUCTS
To document identity, purity, and
strength of investigational product(s)
to be used in the trial
X
11.
RELEVANT
COMMUNICATIONS OTHER
THAN SITE VISITS – letters,
meeting notes, notes of
telephone call
To document any agreements or
significant discussions regarding
trial administration, protocol
violations, trial conduct, adverse
event (AE) reporting
X
X
12.
SIGNED INFORMED
CONSENT FORMS
To document that consent is obtained
in accordance with GCP and protocol
and dated prior to participation of
X 14
15. S. No. Title of Document Purpose
Located in files of
Investigator/
Institution
Sponsor
13.
SOURCE
DOCUMENTS
To document the existence of the subject and
substantiate integrity of trial data collected.
To include original documents related to the
trial, to medical treatment, and history of
subject
X
14.
SIGNED, DATED AND
COMPLETED CASE
REPORT FORMS (CRF)
To document that the investigator or
authorized member of the investigator’s staff
confirms the observations recorded
X
(copy)
X
(original)
15.
DOCUMENTATION OF
CRF CORRECTIONS
To document all changes/additions or
corrections made to CRF after initial data
were recorded
X
(copy)
X
(original)
16.
NOTIFICATION BY
ORIGINATING
INVESTIGATOR TO
SPONSOR OF
SERIOUS ADVERSE
EVENTS AND
RELATED REPORTS
Notification by originating investigator to
sponsor of serious adverse events and related
reports
X
X
15
16. S. No. Title of Document Purpose
Located in files of
Investigator/
Institution
Sponsor
17.
NOTIFICATION BY SPONSOR
AND/OR INVESTIGATOR,
WHERE APPLICABLE, TO
REGULATORY
AUTHORITY(IES) AND
IRB(S)/IEC(S) OF
UNEXPECTED SERIOUS
ADVERSE DRUG REACTIONS
AND OF OTHER SAFETY
INFORMATION
Notification by sponsor and/or
investigator, where applicable, to
regulatory authorities and
IRB(s)/IEC(s) of unexpected serious
adverse drug reactions and of other
safety information.
X
(where
required)
X
18.
NOTIFICATION BY SPONSOR
TO INVESTIGATORS OF
SAFETY INFORMATION
Notification by sponsor to
investigators of safety information
X X
19.
INTERIM OR ANNUAL
REPORTS TO IRB/IEC AND
AUTHORITY(IES)
Interim or annual reports provided
to IRB/IEC and to authority(ies) . X
X
(where
required)
20.
SUBJECT SCREENING LOG To document identification of
subjects who entered pre-trial
screening
X
X
(where
required)
16
17. S. No. Title of Document Purpose
Located in files of
Investigator/
Institution
Sponsor
21.
SUBJECT
IDENTIFICATION
CODE LIST
To document that investigator/institution
keeps a confidential list of names of all
subjects allocated to trial numbers on
enrolling in the trial. Allows
investigator/institution to reveal identity
of any subject.
X
22.
SUBJECT ENROLMENT
LOG
To document chronological enrolment of
subjects by trial number
X
23.
INVESTIGATIONAL
PRODUCTS
ACCOUNTABILITY AT
THE SITE
To document that investigational
product(s) have been used according to
the protocol
X
X
24.
SIGNATURE SHEET To document signatures and initials of all
persons authorized to make entries and/or
corrections on CRFs
X
X
25.
RECORD OF RETAINED
BODY FLUIDS/ TISSUE
SAMPLES (IF ANY)
To document location and identification of
retained samples if assays need to be
repeated
X
X
17
18. S. No. Title of Document Purpose
Located in files of
Investigator/
Institution
Sponsor
1.
INVESTIGATIONAL
PRODUCT(S)
ACCOUNTABILITY AT
SITE
To document that the investigational
product(s) have been used according to the
protocol. To documents the final accounting
of investigational product(s) received at the
site, dispensed to subjects, returned by the
subjects, and returned to sponsor
X X
2.
DOCUMENTATION OF
INVESTIGATIONAL
PRODUCT
DESTRUCTION
To document destruction of unused
investigational products by sponsor or at site
X
(if destroyed at
site)
X
3.
COMPLETED
SUBJECT
IDENTIFICATION
CODE LIST
To permit identification of all subjects
enrolled in the trial in case follow-up is
required. List should be kept in a
confidential manner and for agreed upon
time
X
18
19. S. No. Title of Document Purpose
Located in files of
Investigator/
Institution
Sponsor
16.
FINAL TRIAL CLOSE-OUT
MONITORING REPORT
To document that all activities
required for trial close-out are
completed, and copies of essential
documents are held in the appropriate
files
X
17.
AUDIT CERTIFICATE (if
available)
To document that audit was
performed
X
18.
TREATMENT ALLOCATION
AND DECODING
DOCUMENTATION
Returned to sponsor to document any
decoding that may have occurred X
19.
FINAL REPORT BY
INVESTIGATOR TO IRB/IEC
WHERE REQUIRED, AND
WHERE APPLICABLE, TO
THE REGULATORY
AUTHORITY(IES)
To document completion of the trial
X
20.
CLINICAL STUDY REPORT To document results and
interpretation of trial
X
X
19
20. Integrated addendum to ICH E6(R1): Guidelines for good clinical
practice E6(R2) , current step 4 version dated 9 November 2016.
20